Fresh analysis reveals that people who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain lost weight much more quickly than those who end conventional diet and exercise programs.
Research printed in a major medical journal demonstrates that while overweight individuals often shed about a fifth of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People using these medications need to be informed of the risk of quick rebound weight gain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to original mass within about one and a half years.
Analyzing Approaches
The analysis, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of the injectable medications with other pills.
Researchers note that people who shed pounds through diet and exercise generally have a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Doctors believe the mode of action of the drugs accounts for the amplified rebound.
These medications copy a natural hormone called GLP-1, which helps regulate hunger.
"Artificially providing the hormone concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication means hunger is no longer kept in check, making excessive eating a significant risk."
A Lifelong Issue?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, due to the significant potential of relapse, the treatment might need to be ongoing.
This view is supported by drug manufacturers, who note that the findings "highlight the persistent nature of excess weight," akin to managing conditions like hypertension.
Patient Testimonies
Users who have discontinued the jabs explain a intense resurgence of cravings.
"I experienced a switch flipping and I was suddenly starving," described an individual.
The struggle is worsened if users have not established sustainable dietary or behavioural modifications during therapy.
Growing Interest
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Use is more common among females compared to men.
- The middle-aged age group shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent fix and maintained weight loss likely depends on integrated behavioural changes.
